Cerus (CERS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Cerus

NasdaqGM•Healthcare•Medical Devices

$2.54-0.05(-0.02%)Pre-market

Market Cap

$531.50M

P/S

2.1x

P/B

7.6x

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

How this company scores

WeakMetricSide Score: 53/100

Grade capped at D — Interest coverage below 1× (-0.2x) — earnings cannot cover interest. Strongest: Growth (20/25); weakest: Cash & Earnings Quality (4/25).

Profitability14/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Growing revenueLong cash runwayLow leverageProfit converts from growth

Grade capped at D

Interest coverage below 1× (-0.2x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 2.1x5y range 1.3x – 7.6x

Currently near its 20-quarter median.

P/B · 7.6x5y range 4.7x – 14.2x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $531.50M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $249.22M
Q. Revenue: $57.44M
TTM EBITDA: $792,000
TTM Op. Income: $-1.62M
Q. Op. Income: $-1.86M
TTM Net Income: $-6.78M
Q. Net Income: $-2.94M
EPS: $-0.01
Shares Out.: $200.56M

$249.22M in TTM revenue grew 16.7% YoY, reaching $57.44M last quarter. TTM EBITDA of $792,000 and TTM operating income of $-1.62M show growth is flowing through to the bottom line. However, net income is negative at $6.78M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 51.4%
EBITDA Margin: -2.4%
Op. Margin: -3.2%
Net Margin: -5.1%

Op. margin of -3.2% is up 3.3% YoY — cost efficiency is improving. Net margin at -5.1% and gross margin of 51.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 50% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.1x
P/B Ratio: 7.6x

P/S of 2.1x and P/B of 7.6x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $205.19M
Cash: $17.98M
Long-Term Debt: $34.83M
Book Value: $70.02M
D/E Ratio: 0.5
Debt/EBITDA: N/A

With $205.19M in assets and $34.83M in long-term debt, D/E is 0.5and book value is $70.02M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 51% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-2.66M
TTM Free Cash Flow: $-1.83M
FCF Margin: -0.7%
FCF / Net Income: 0.3

TTM FCF of $-1.83M on $-2.66M in operating cash flow. The FCF / Net Income ratio of 0.3x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.